London, UK-based Cell Medica has received European Commission orphan drug designations for its lead cancer immunotherapy CMD-003.
The title recounts to the treatment for extra nodal NK/T-cell lymphoma, an unusual type of non-Hodgkin lymphoma, and post-transplant lymph proliferative disorder, a state originated by B-cell propagation due to therapeutic immune containment after organ transplantation.
CMD-003 is made of the patient’s immune cells which have been triggered to kill malignant cells expressing antigens linked with the oncogenic Epstein Barr virus (EBV).
This therapy has the likely to address a range of EBV-linked lymphomas, nasopharyngeal carcinoma and gastric cancer; the EU orphan title will provide the firm with dogmatic and financial inducements for growing and marketing CMD-003, along with a ten-year period of marketing inimitability after product endorsement.
According to Gregg Sando, Cell Medica’s chief executive “CMD-003 is a new cellular immune therapy with the prospective to make over the way we treat patients with EBV-associated lymphomas. We are now testing this product in our CITADEL Phase II test for patients with highly developed extra nodal NK/T cell lymphoma and look forward to finishing point of the study next year.
Date: July 21st, 2016
http://www.pharmatimes.com/news/eu_orphan_status_for_cell_medica_drug_1077305